Another major international collaborative work NCI Center for Cancer Research #Chulabhorn is out. Congrats to Benjarath Pupacdi Chris Loffredo Anuradha Budhu LCP & all members of #TIGER-LC consortium for over 14 years of dedication and hard work. More to come! onlinelibrary.wiley.com/doi/10.1002/ij…

Nature research paper: Acquisition of epithelial plasticity in human chronic liver disease go.nature.com/4aBDy7E

Trastuzumab deruxtecan in solid tumours with activating HER2 mutations The Lancet Oncology doi.org/10.1016/S1470-… 🔎DESTINY-PanTumor01, 100 pts, 20% Biliary 👉ORR 29·4%, mPFS 4.5 mo, mOS 10.0 mo 🧐Activity "encouraging", but we need additional biomarker ESMO - Eur. Oncology EASL Education ILCA

chatomics! How to convert raw counts to TPM for TCGA data and make a heatmap across cancer types divingintogeneticsandgenomics.com/post/how-to-co…

For readers interested in approaches for extracellular targeted protein degradation, here's a comprehensive review bit.ly/489BXVZ rdcu.be/dLaX8

In the latest issue! ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity dlvr.it/T8b9K0

A comprehensive analysis of omics data from biopsies and blood samples from more than 12,000 cases of heart, lung, liver and kidney transplants provides insights into shared mechanisms of #allograft dysfunction across organs University of Sydney nature.com/articles/s4159…

🆕REVIEW❕ Immunotherapy for hepatocellular carcinoma ➡️The next evolution in expanding access to liver transplantation Full text here👉journal-of-hepatology.eu/article/S0168-… #LiverTwitter

1/ Cancer cell lines and mice are critical models for studying cancer. 7 data resources for cancer cell lines and mouse models:🧵

For readers interested in novel drugs for inflammatory bowel diseases, here's a recent article discussing how to address challenges at key steps in the discovery and development pathway bit.ly/44Wys4z rdcu.be/dOeeP

CUT&Tag and mRNA sequencing in single cells creates a comprehensive map of the epigenetic landscape during human neural development rna-seqblog.com/cuttag-and-mrn… #journals #feedly

Macrophages are terrible at migrating. In contrast, their precursor cells - monocytes - are highly motile. Monocytes exploit interleukin 6 (IL-6) secreted by cancer cells and themselves to migrate fast and promote cancer cell proliferation. More here: biorxiv.org/content/10.110…

Trastuzumab Deruxtecan in HER2–Expressing BTC Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎HERB phs II 🇰🇷, 32 pts 👉ORR 36%, mPFS 5.1 mo, mOS 7.1 mo 🧐disappointing OS for selected subgroup. IO- combinations? Front-line? ESMO - Eur. Oncology EASLnews ILCA

For readers interested in inflammasome signalling as a therapeutic target, here's a comprehensive review nature.com/articles/s4157… rdcu.be/dRHBe

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma | Nature Communications. Interesting article on Lenvatinib nature.com/articles/s4146…

Online Now: Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors dlvr.it/TCb3kZ

Happy to share our narrative review of the natural history of MASLD in The Lancet Gastroenterology & Hepatology Link: thelancet.com/journals/langa… Ying Shang Patrik Nasr Hannes Hegmar #LiverTwitter Karolinska Institutet

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…

Excited to share a commentary on emerging challenges in understanding and targeting cancer genome instability to improve patient outcomes: bit.ly/3XoSstk Thanks to Cancer Discovery for the opportunity and to everyone else from the AACR NextGen Stars Program who contributed!

Happy to share an article from a friend Jun Hee Lee group. The method paper makes the cell type identification much more accurate for spatial transcriptomics: FICTURE: scalable segmentation-free analysis of submicron-resolution spatial transcriptomics pubmed.ncbi.nlm.nih.gov/39266749/